Fast-growing CRO adopts Veeva Vault Clinical Suite to drive
greater efficiency and visibility across global studies
PLEASANTON, Calif.--(BUSINESS WIRE)--
Veeva
Systems (NYSE: VEEV), today announced that Ora, Inc., a leading
ophthalmic CRO, adopted the Veeva
Vault Clinical Suite to unify its clinical systems and processes.
Ora is bringing together CTMS, eTMF, and study start-up applications on
one platform to improve operational efficiency and visibility throughout
its clinical trials. Now Ora can increase collaboration among internal
stakeholders and sponsors to deliver faster, higher quality studies.
“We needed new technology to streamline clinical operations,” said
Edward Leftin, manager of clinical information systems at Ora, Inc.
“Veeva’s suite of unified clinical applications helps our study teams
work more efficiently. Now we can manage information and end-to-end
trial processes, from site activation to study closeout.”
Ora’s transition to a unified clinical environment started with Veeva
Vault eTMF, helping clinical teams manage documents and processes in
real-time as the TMF is generated, improving inspection readiness and
reducing study close out time from weeks to days. The addition of Veeva
Vault Study Startup enables Ora to speed global site selection and
activation, while Veeva
Vault CTMS empowers clinical teams with greater insights across the
trial lifecycle for proactive trial management.
Veeva Vault Clinical Suite makes it easy for teams to share the same
trial documents and data to make better, more informed decisions. For
example, as site documents such as site monitoring reports or CVs are
created in Vault CTMS or Vault Study Startup, they automatically become
part of the TMF. This reduces manual steps and enables cross-functional
teams, including sponsors, to leverage information in real-time.
“CROs are leading the industry-wide shift to unify clinical operations
and build more collaborative, strategic partnerships with sponsors,”
said Jennifer Goldsmith, senior vice president of Veeva Vault. “Ora is a
great example of how the Veeva Vault Clinical Suite is helping break
down system and process silos to improve study execution and quality.”
Vault CTMS, Vault eTMF, and Vault Study Startup are part of the Veeva
Vault Clinical Suite, the industry’s first cloud platform that
combines EDC, CTMS, eTMF, and study start-up to unify clinical data
management and operations. Vault Clinical applications are now used by
more than 170 customers, including eight of the top 20 biopharmaceutical
companies deploying globally.
Additional Information
For more on Veeva Vault Clinical Suite, visit: veeva.com/Clinical
Connect
with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veevasystems on Twitter: twitter.com/veevasystems
Like
Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 600 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended October 31, 2017. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180306005561/en/
Source: Veeva Systems Inc.